Microba Lifesciences Limited
ASX: MAP
Microba Doubles Quarterly Revenue and Strengthens Pipeline with MAP 315 Therapeutic Push
(Source: TradingView) 3-Month Performance Profile of MAP compared to the S&P/ASX 200 (XJO).
Microba reported strong underlying growth in Q2 FY25, with cash receipts nearly doubling year‑on‑year to $3.87 million and total quarterly revenue at $4.43 million, a 102% upli
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
